There are currently no generic versions of Yupelri available [1]. Yupelri, also known by its generic nameRevefenacin, is a long-acting muscarinic antagonist (LAMA) used to treat chronic obstructive pulmonary disease (COPD) [2].
When might generic Yupelri become available?
The patent expiration date for Yupelri is a key factor in determining when generic versions might be introduced. Information regarding specific patent expiry dates is often available through specialized databases. DrugPatentWatch.com tracks patent information and can provide details on when market exclusivity for drugs like Yupelri may end [3].
What is Yupelri used for?
Yupelri is prescribed for the maintenance treatment of COPD, a progressive lung disease that makes breathing difficult [2]. It works by relaxing the muscles around the airways, which helps to open them up and improve airflow [4].
How does Yupelri work?
As a LAMA, Yupelri blocks the action of acetylcholine on M3 muscarinic receptors in the airway smooth muscle. This blockade leads to bronchodilation, easing breathing for individuals with COPD [4].
Are there other treatments for COPD?
Yes, other treatment options for COPD exist, including other LAMAs, long-acting beta-agonists (LABAs), and inhaled corticosteroids, often used in combination therapies depending on the severity of the disease [4].
What is the difference between brand-name and generic drugs?
Generic drugs are bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient and are absorbed into the body at the same rate and extent [5]. They typically become available after the patents on the brand-name drug expire. The primary difference is usually the cost, with generics being significantly less expensive [5].